

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 39/12, 39/205, 39/235, C12N 7/01, 15/00, 15/09</b>		<b>A1</b>	(11) International Publication Number: <b>WO 96/39178</b>
			(43) International Publication Date: 12 December 1996 (12.12.96)
(21) International Application Number: <b>PCT/US96/09495</b>			PA 19085 (US). WILSON, James, M. [US/US]; 1350 N. Avignon Drive, Gladwyne, PA 19035 (US).
(22) International Filing Date: <b>5 June 1996 (05.06.96)</b>			(74) Agents: BAK, Mary, E. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US).
(30) Priority Data: 08/461,837 5 June 1995 (05.06.95) US 60/000,078 8 June 1995 (08.06.95) US			(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(60) Parent Applications or Grants (63) Related by Continuation US 08/461,837 (CIP) Filed on 5 June 1995 (05.06.95) US 60/000,078 (CIP) Filed on 8 June 1995 (08.06.95)			<b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(71) Applicants (for all designated States except US): THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY [US/US]; 36th & Spruce Streets, Philadelphia, PA 19104-4268 (US). TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 133 South 36th Street, Philadelphia, PA 19104-3246 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): ERTL, Hildegund, C., J. [DE/US]; 1929 West Montgomery Avenue, Villanova,			
(54) Title: A REPLICATION-DEFECTIVE ADENOVIRUS HUMAN TYPE 5 RECOMBINANT AS A VACCINE CARRIER			
(57) Abstract <p>A replication defective recombinant adenovirus is provided which contains a complete deletion of its E1 gene and at least a partial deletion of its E3 gene, said virus containing in the site of the E1 deletion a sequence comprising a non-adenovirus promoter directing the replication and expression of DNA encoding a heterologous protein from a disease-causing agent, which, when administered to a mammal in said recombinant virus, elicits a substantially complete protective immune response against the agent. Pharmaceutical and veterinary products containing the recombinant adenovirus are provided.</p>			

20413  
#3

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

A REPLICATION-DEFECTIVE ADENOVIRUS HUMAN TYPE 5  
RECOMBINANT AS A VACCINE CARRIER

This invention was supported by the National Institutes of Health Grant Nos. NIH AI 33683-02 and NIH  
5 AI 27435-05. The United States government has certain rights in this invention.

Field of the Invention

This invention relates generally to recombinant adenoviruses as vaccine components, and more  
10 particularly, to the use of replication deficient adenoviruses as vaccine carriers, which induce protective immune responses in mammalian hosts.

Background of the Invention

A replication competent, recombinant adenovirus  
15 (Ad) is an adenovirus with intact or functional essential genes, (i.e., E1a, E1b, E2a, E2b and E4). Such recombinant viruses containing a variety of inserted genes have been used as vaccine compositions with some success [see, e.g. Davis, U.S. Patent No. 4,920,309].

20 One of these recombinant adenoviruses expressing the rabies G protein was shown to induce protective immunity in animals upon challenge with rabies virus [L. Prevac, J. Infect. Dis., 161:27-30 (1990)]. However, doses above  $10^6$  plaque-forming units (pfu) of  
25 this replication-competent virus were required to induce complete protection to viral challenge. Further, the use of these viruses in a live form capable of replicating in vivo is an undesirable attribute of a vaccine component.

In contrast, adenoviruses which have been made  
30 replication deficient by deletion of the Ad E1a and E1b genes have been used primarily for gene therapy protocols [See, e.g., Kozarsky and Wilson, Curr. Opin. Genet. Dev., 3:499-503 (1993); Kozarsky et al, Som. Cell Mol. Genet., 19:449-458 (1993); see also, International Patent

Application No. WO95/00655, published Jan. 5, 1995].

Such recombinant, replication deficient adenoviruses have been found to induce cell-mediated immune responses [Y. Yang et al, Proc. Natl. Acad. Sci. USA, 91:4407 (1994) and Y. Yang et al, Immunity, 1:433-442 (August 1994)] and neutralizing antibodies [T. Smith et al, Gene Therapy, 5:397 (1993); K. Kozarsky et al, J. Biol. Chem., 269:13695 (1994)]. None of these articles relating to the use of recombinant replication deficient Ad in gene therapy have measured the induction of a protective immune response.

Others have described the insertion of a foreign gene into a replication-defective adenovirus for putative use as a vaccine [See, e.g. T. Ragot et al, J. Gen. Virol., 74:501-507 (1993); M. Eliot et al, J. Gen. Virol., 71:2425-2431 (1990); and S. C. Jacobs et al, J. Virol., 66:2086-2095 (1992)]. Jacobs et al, cited above, describes a recombinant E1-deleted, E3 intact, Ad containing encephalitis virus protein NS1 under the control of a heterologous cytomegalovirus (CMV) promoter. When mice were immunized with the recombinant Ad vaccines and challenged with virus, Jacobs et al obtained only partial protection (at most a 75% protection) for an average survival of 15 days. Eliot et al, cited above, describe a recombinant E1-deleted, partially E3-deleted Ad with pseudorabies glycoprotein 50 inserted into the E1 deletion site under the control of a homologous Ad promoter. In rabbits and mice, after immunization and challenge, only partial protection was obtained (i.e., about one-third). Ragot et al, cited above, describe a recombinant E1-deleted, partially E3-deleted Ad with Epstein Barr virus glycoprotein gp340/220 inserted into the E1 deletion site under the control of a homologous Ad promoter. In marmosets (tamarins) after three high dose ( $5 \times 10^9$  pfu,  $1 \times 10^{10}$  pfu and  $2 \times 10^{10}$  pfu), intramuscular

immunizations and viral challenge, full protection was obtained.

For certain highly infectious diseases, such as rabies, there is a demand for an effective vaccine.

5 Desirably, a vaccine should be effective at a low dosage to control the occurrence of side effects or to enable sufficient amounts of vaccine to be introduced into animals in the wild. Currently, a vaccinia rabies glycoprotein (VRG) vaccine is being used for oral wild-  
10 life immunization [B. Brochier et al, Vaccine, 12:1368-1371 (1994)]. However, doses above  $10^6$  pfu are required to induce complete protection.

There thus remains a need in the art for a method of vaccinating against various disease states, and  
15 particularly rabies, which is safe and highly effective.

#### Summary of the Invention

The inventors have surprisingly found compositions and methods of vaccinating a human and/or animal against a disease using an adenovirus defective  
20 vaccine composition, which produces a high level of protection upon administration of a low vaccine dose. For example, vaccination with a vaccine composition described herein, which is directed against rabies, has been found to require as little as a single dose of  $10^4$   
25 pfu of rabies vaccine vector to induce complete protection. This effect is also accomplished by administration routes other than the oral route.

Thus, in one aspect, the invention provides a replication-defective recombinant adenovirus (rAd)  
30 vaccine containing DNA encoding a selected heterologous protein from a disease-causing agent, which elicits a protective immune response against the agent. This recombinant adenovirus of the invention contains at least a partial, but functional, deletion of the Ad E3 gene.

Further in the site of the Ela/E1b deletion which renders the Ad replication-defective, the recombinant virus contains a sequence comprising a non-adenovirus promoter directing the replication and expression of the DNA  
5 encoding the heterologous protein. For example, an exemplary rAd is Adrab.gp, which contains a rabies gp gene and is useful in a method for treating or preventing rabies.

In another aspect, the invention provides  
10 pharmaceutical and veterinary compositions which contain the rAd of the invention.

In still another aspect, the invention provides for the use of the rAd in the manufacture of the compositions described above.

15 In yet a further aspect, the invention provides a method of vaccinating a human or animal against disease comprising administering to said human or animal an effective amount of a replication-defective recombinant adenovirus vaccine containing DNA encoding a selected  
20 heterologous protein which elicits a protective immune response against an agent causing the disease. This adenovirus of the invention contains at least a partial, but functional, deletion of the Ad E3 gene. Further in the site of the Ela/E1b deletion which renders the Ad  
25 replication-defective, the recombinant virus contains a sequence comprising a non-adenovirus promoter directing the replication and expression of the DNA encoding the heterologous protein.

In another aspect, the present invention  
30 provides a method of preventing rabies infection in an animal comprising administering to the animal an effective amount of a recombinant replication-defective Adrab.gp adenovirus containing DNA encoding a rabies virus glycoprotein.

Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

Brief Description of the Drawings

5                    Fig. 1A is a schematic representation of the 1650 bp rabies glycoprotein gene from Evelyn Rockitniki Abelseth strain excised from the pSG5.ragp plasmid by cleavage with BglII. The 1650 bp sequence spans nucleotide 1178 to 2827 of SEQ ID NO: 1.

10                   Fig. 1B is a schematic map of the pAd.CMVlacZ (also known as H5.020CMVlacZ) plasmid, which contains adenovirus map units (m.u.) 0-1 as represented by the black bar at the top of the circular plasmid, followed by a cytomegalovirus enhancer/promoter (CMV enh/prom) represented by the striped arrow to the right of the black bar, a human betagalactosidase gene represented by the dark gray bar at the righthand side of the circular plasmid; a polyadenylation signal represented by the short white bar at the bottom of the circular plasmid, adenovirus m.u. 9-16 represented by the long black bar at the lower lefthand portion of the circular plasmid and plasmid sequences from plasmid pAT153 including an origin of replication and ampicillin resistance gene represented by the light gray bar at the upper lefthand portion of the circular plasmid. Restriction endonuclease enzymes are represented by conventional designations in this plasmid. NotI digestion removes the LacZ gene from this plasmid.

25                   Fig. 1C is a schematic map of the plasmid pAdCMV.ragp which results from blunt end cloning of the BglII fragment of pSG5.ragp to the larger NotI fragment of pAdCMV.lacZ. pAdCMV.ragp is substantially similar to the pAd.CMVlacZ plasmid, but which contains the rabies glycoprotein sequence in place of the lacZ gene.

pAdCMV.rapgp [SEQ ID NO: 1] contains adenovirus m.u. 0-1 as represented by the black bar at the top of the circular plasmid (nucleotides 12 to 364 of SEQ ID NO: 1); followed by a cytomegalovirus enhancer/promoter (CMV enh/prom) represented by the striped arrow to the right of the black bar [nucleotides 382 to 863 of SEQ ID NO: 1]; a rabies glycoprotein gene represented by the dotted bar at the righthand side of the circular plasmid (nucleotides 1178 to 2827 of SEQ ID NO: 1); a polyadenylation signal represented by the short white bar at the lower righthand portion of the circular plasmid [nucleotides 2836-3034 of SEQ ID NO: 1]; adenovirus m.u. 9-16 represented by the long black bar at the lower portion of the circular plasmid (nucleotides 3061 to 5524 of SEQ ID NO: 1); and plasmid sequences from plasmid pAT153 including an origin of replication and ampicillin resistance gene represented by the light gray bar at the upper lefthand portion of the circular plasmid (nucleotides 5525 to 8236 of SEQ ID NO: 1). Restriction endonuclease enzymes are represented by conventional designations. SEQ ID NO: 2 provides the rabies protein sequence encoded by the nucleotide sequence within pAdCMV.rabgp.

Fig. 1D is a schematic map of recombinant adenovirus Adrab.gp (also known as H5.020CMV.rab), which results from homologous recombination between pAdCMV.rabgp and Ad strain dl7001. Ad dl7001 is an Ad5 variant that carries an approximately 3 kb deletion of the Ad5 sequence (GenBank Accession No. M73260) between m.u. 78.4 through 86. The CMV/rabies glycoprotein/pA minicassette of pAd.CMVrab is inserted between deleted adenovirus m.u.1 and 9, with the remaining Ad5 m.u. 9-100 having the above mentioned E3 gene deletion. Restriction endonuclease enzymes are represented by conventional designations.



Fig. 2 is a bar graph plotting  $^3\text{H}$ -thymidine ([ $^3\text{H}$ ]TdR) incorporation, measured at counts per minute  $\pm$  standard deviation (cpm  $\pm$  SD), for irradiated splenocytes plated at  $5 \times 10^5$  cells per well of a round bottom microtiter plate and incubated with 5 (diagonally striped), 1 (cross-hatched) or 0.2 (solid)  $\mu\text{g/ml}$  of betapropionolactone-inactivated Evelyn Rockitniki Abelseth rabies strain (ERA-BPL) or approximately 1 (diagonally striped), 0.1 (cross-hatched), and 0.01 (solid) pfu of Adrab.gp per cell or medium only as a negative control for 60 minutes at  $37^\circ\text{C}$ . As described in Example 2B, after cloned T cells were added, cells were pulsed two days later for 6 hours with  $^3\text{H}$ -thymidine, harvested and counted in a  $\beta$ -counter.

Fig. 3A is a graph plotting % specific lysis (means of triplicates  $\pm$  SD) vs. effector:target cell ratio for groups of C3H/He mice inoculated with  $2 \times 10^6$  pfu of Adrab.gp (solid box) or H5.020CMVlacZ (open box), as described in Example 4B. Splenocytes were harvested 14 days later and co-cultured for 5 days with 1 pfu of Adrab.gp virus per cells. Activated lymphocytes were then tested at different E:T ratios on H-2 compatible L929 cells stably transfected with a rabies virus G protein-expressing vector (t.L929rab.gp) in a 4 hour  $^{51}\text{Cr}$ -release assay.

Fig. 3B is a graph of an experiment similar to Fig. 3A, but in which the activated lymphocytes were tested at different E:T ratios on H-2 compatible L929 cells stably transfected with a neomycin-expressing vector (t.L929.neo) in the  $^{51}\text{Cr}$ -release assay, as a control.

Fig. 4A is a graph plotting number of cells vs. intensity of fluorescence for L929 fibroblasts plated in 24-well Costar plates in medium supplemented with 2% fetal bovine serum (FBS) following infection with 1

pfu/cell of VRG, as described in Example 5 below. Cells harvested 12 hours after infection and stained by indirect immunofluorescence with monoclonal antibody (MAb) 509-6 were analyzed by fluorescence activated cell sorting (FACS). The line on the graph labeled "B" is the threshold below which 99% of the population are negative. Line "C" represents the region that encompasses all events on the histogram.

Fig. 4B is a graph similar to Fig. 4A above, except the cells were harvested 36 hours after infection.

Fig. 4C is a graph similar to Fig. 4A above, except the cells were harvested 60 hours after infection.

Fig. 4D is a graph similar to Fig. 4A above, except the cells, harvested 12 hours after infection, were stained using cells treated only with the fluorescein isothiocyanate (FITC)-labeled goat anti-mouse immunoglobulin (Ig) as a control.

Fig. 4E is a graph similar to Fig. 4D above, except the cells were harvested 36 hours after infection.

Fig. 4F is a graph similar to Fig. 4D above, except the cells were harvested 60 hours after infection.

Fig. 4G is a graph similar to Fig. 4A above, except the cells were infected with 1 pfu Adrab.gp virus, and cells were harvested 12 hours after infection.

Fig. 4H is a graph similar to Fig. 4G, except the cells were harvested 36 hours after infection.

Fig. 4I is a graph similar to Fig. 4G, except the cells were harvested 60 hours after infection.

Fig. 4J is a graph similar to Fig. 4G above, except the cells were stained by indirect immunofluorescence using cells treated only with FITC-labeled goat anti-mouse Ig as a control.

Fig. 4K is a graph similar to Fig. 4J above, except the cells were harvested 36 hours after infection.

Fig. 4L is a graph similar to Fig. 4J above, except the cells were harvested 60 hours after infection.

Fig. 5A is a graph plotting optical density at 405 nm vs. serum dilution for duplicate samples  $\pm$  SD, as described in Example 6B below for mice immunized with a replication-competent E3 deleted adenovirus (open box) or Adrab.gp (solid box). Native age-matched control mice were used as controls (X). Mice were bled 10 days after immunization and serum antibody titers to adenoviral antigens were determined by an ELISA on plates coated with 1  $\mu$ g/mL of purified H5.020CMVlacZ virus.

Fig. 5B is a graph similar to that of Fig. 5A for mice immunized as described in Fig. 6A below, and bled at 16 days.

Fig. 6A is a graph plotting mean percentage (%) specific lysis of triplicates  $\pm$  SD vs. E:T cell ratio for C3H/He mice inoculated with  $10^6$  pfu of replication competent E3 deleted adenovirus and boosted 3 weeks later with Adrab.gp (open box). Control mice were inoculated with Adrab.gp only (solid box). Mice were sacrificed 4 weeks later and upon restimulation with 1 pfu of Adrab.gp per cell tested on a 4 hour  $^{51}\text{Cr}$ -release assay on L929 cells stably transfected with pSG5rab.gp. See Example 6.

Fig. 6B is a graph similar to Fig. 6A, except the L929 cells were transfected with pSV2neo.

Fig. 7 is a graph plotting % survival of vaccinated mice vs. days after challenge with rabies virus. Mice were challenged 3 days (open triangle), 7 days (open square), and 10 days (solid square) after vaccination. X represents naive mice controls. See, Example 7.

#### Detailed Description of the Invention

The present invention provides compositions and methods of effectively inducing a protective immune

response to a disease agent. The compositions include a recombinant replication-defective adenovirus, and pharmaceutical and veterinary compositions containing the rAd. The rAd backbone was previously used for gene  
5 therapy. As discussed herein, the inventors have surprisingly found that use of such a recombinant Ad, described in detail below, provides substantially complete immune protection in vaccinates.

By "substantially complete" protection is meant  
10 when administered in an effective amount, the recombinant adenovirus presents an immunogenic protein in such a manner that a protective immune response is observed in substantially all vaccinates after a single administration. By "substantially all" is meant greater  
15 than 90% of the vaccinates. Unexpectedly, the recombinant vaccine permits successful vaccination with very few booster administrations. Also unexpectedly, the recombinant vaccine permits vaccination at an unexpectedly lower dosage than is normally used in  
20 similar vaccines in which the same protein is present in another recombinant virus. For example, immunization of mice with a single dose of as little as  $10^4$  pfu of the recombinant, replication defective Ad containing a rabies glycoprotein has been observed to induce complete  
25 protection against rabies infection. Partial protection was seen seven days after immunization.

While not wishing to be bound by theory, the inventors currently believe that this recombinant, replication defective Ad vaccine is advantageous over,  
30 e.g., the vaccinia vaccine, because it permits lower doses of antigen to be expressed for an extended period of time by a non-lytic virus. For example, although vaccinia expresses higher doses of antigen, e.g., a rabies antigen, it is a lytic virus which causes a rapid  
35 demise of infected cells. The finding that the

recombinant replication-defective Ad, e.g., Adrab.gp virus, used in the method of the present invention is more efficacious than the currently used vaccinia rabies (VRG) vaccine is unexpected and incompatible with current thinking that the antigenic dose governs the magnitude of the immune response. The use of the recombinant replication defective adenovirus also confers safety and efficacy advantages over other vaccine carriers, such as vaccinia. The adenovirus construct results in slow accumulation of the rabies virus G protein on the surface of infected cells without causing visible cell damage (data not shown). In contrast, cells infected with VRG recombinant rapidly express substantial amounts of the rabies virus G protein on the cell surface but then die shortly after infection. The adenoviral construct persists for at least seven days in immunocompetent mice.

With respect to safety, the present invention provides a recombinant replication-defective Ad which is thus highly unlikely to spread within a host or among individuals, particularly in view of the fact that the recombinant, E1-deleted dl7001 Ad virus, which is the backbone of the exemplary replication defective recombinant Ad used in the examples below has already been approved for use in humans for gene therapy, i.e., for the replacement of faulty or missing genes. The recombinant virus lacks oncogenic potential because the E1 gene that can function as an oncogene in some adenovirus strains has been deleted. Further, cells infected with the recombinant, replication defective adenovirus are completely eliminated by CD8 T cells within 21 days in immunocompetent hosts.

With respect to efficacy, the recombinant, replication defective Ad of this invention is highly efficacious at inducing cytolytic T cells and antibodies to the inserted heterologous protein expressed by the

virus. This has been demonstrated with a recombinant, replication defective Ad containing a sequence encoding the rabies virus glycoprotein as the heterologous gene, which Ad has been administered to animals by other than the oral route.

The recombinant virus of this invention is also surprisingly more effective as a vaccine than other, previously reported, replication defective adenovirus vaccines. See, for example, Ragot et al, Eliot et al, and Jacobs et al, all cited above. In contrast to the other replication defective adenovirus vaccines, the vaccine composition useful in the present invention can be used at lower doses. This vaccine can also be administered in a single inoculation to obtain substantially complete protection.

For these reasons, the recombinant replication-defective adenovirus of the invention and particularly the preferred embodiment which makes use of the pAdCMV.lacZ (or H5.020CMVlacZ) Ad vector described below, can be used as a prophylactic or therapeutic vaccine against any pathogen for which the antigen(s) crucial for induction of an immune response able to limit the spread of the pathogen has been identified and for which the cDNA is available.

#### I. The Recombinant Adenovirus

As used herein, the term "minicassette" refers to the nucleotide sequence comprised of (a) a non-Ad promoter, which directs the replication and expression of (b) the following nucleotide sequence which encodes a heterologous protein immunogen, which is followed by (c) a polyA nucleotide sequence. By "vector or plasmid" is meant the construct comprised of 5' sequences of the Ad virus (usually Ad m.u. 0-1) deleted of the E1 gene (which occurs between Ad m.u. 1-9), which may contain a heterologous nucleotide sequence, but which does not

contain the 3' end of the Ad virus (generally between about Ad m.u. 16 to 100), but rather conventional plasmid sequences. This vector does not contain all of the genes essential to a replicative virus. By "recombinant, replication defective Ad" is meant the infectious recombinant virus, deleted of its E1 gene, into which location is inserted the minicassette, and which contains all of the 3' sequences essential to an infectious virus except for a functional deletion in the E3 gene region.

10           The recombinant virus of the method of the invention is a replication-defective recombinant adenovirus containing a deletion of its E1 gene and at least a partial, functional deletion of its E3 gene. In the site of the E1 deletion a minicassette is inserted, 15 which comprises a nucleotide sequence encoding a heterologous protein immunogen and a non-adenovirus promoter directing the replication and expression of the nucleotide sequence encoding the heterologous protein.

Any Ad that infects the target cells is 20 appropriate for use in this invention. Desirable adenoviruses are human type C adenoviruses, including serotypes Ad2 and Ad5. The DNA sequences of a number of adenovirus types, including type Ad5, are available from GenBank [Accession No. M73260]. The adenovirus sequences 25 may be obtained from any known adenovirus type, including the presently identified 41 human types [Horwitz et al, Virology, 2d ed., B. N. Fields, Raven Press, Ltd., New York (1990)]. Similarly, adenoviruses known to infect other animals may also be employed in this invention.

30           The selection of the adenovirus type and strain is not anticipated to limit the following invention. A variety of adenovirus strains are available from the American Type Culture Collection, Rockville, Maryland, or available by request from a variety of commercial and 35 institutional sources. In the following exemplary

embodiment, an adenovirus type 5 (Ad5) sequence obtained from GenBank [Acc. No. M73260] is used for convenience.

Adenoviruses of the present invention are replication defective, i.e., intact adenoviruses which  
5 have been rendered replication defective by deleting the early gene locus that encodes E1a and E1b. See, K.F. Kozarsky and J. M. Wilson, Curr. Opin. Genet. Dev., 3:499-503 (1993). Similarly, a replication defective adenovirus may be designed by deleting less than the  
10 entire E1a and E1b locus, but enough to functionally disable the E1 genes.

An additional characteristic of the Ad useful in this invention is that the E3 gene is deleted, i.e., from about m.u. 78.5 to about m.u. 84.3 of Ad5. While  
15 the presently preferred embodiment contains a complete deletion of that sequence, it may be possible to partially delete the E3 sequence to disable the functional abilities of the E3 gene.

A preferred recombinant Ad virus may be  
20 produced by using a plasmid vector pAd.CMVlacZ as described in Fig. 1B. This plasmid contains adenovirus sequences Ad m.u. 0-1 (i.e., it is fully deleted of E1a and E1b genes), after which a selected minigene may be inserted, e.g., the rabies glycoprotein under control of  
25 a heterologous promoter and other regulatory sequences, if desired, followed by the sequence Ad m.u.9 to 16 and plasmid sequences. When this vector is manipulated to place a minicassette into the E1 deletion site, and supplied with the remaining 3' Ad sequences with a full  
30 deletion of E3 and cultured in a helper cell line, the resulting recombinant adenovirus is capable of functioning as a rabies vaccine. This recombinant virus, called Adrab.gp or H5020.CMVrab, is described in detail in Example 1 and in flow chart form in Figs. 1A through  
35 1D.



The preferred recombinant Ad of this invention contains a minicassette which uses the cytomegalovirus (CMV) promoter [see, e.g., Boshart et al, Cell, 41:521-530 (1985)] to control the expression of the inserted  
5 heterologous gene. The promoter is inserted in the site of the E1 deletion and directs the replication and expression of the protein encoded by the selected heterologous gene. However, this invention is not limited by the selection of the promoter, except that the  
10 promoter should be heterologous to the Ad virus, i.e., the E1 Ad promoter is replaced using techniques known to those of skill in the art. Other desirable promoters include the Rous sarcoma virus LTR promoter/enhancer, the SV40 promoter, and the chicken cytoplasmic  $\beta$ -actin  
15 promoter [T. A. Kost et al, Nucl. Acids Res., 11(23):8287 (1983)]. Still other promoter/enhancer sequences may be readily selected by one of skill in the art.

As discussed above, in the site of the E1 deletion, and under control of a promoter heterologous to  
20 Ad, a nucleic acid sequence, preferably in the form of DNA, encoding a protein heterologous to the Ad is inserted using techniques known to those of skill in the art.

The heterologous nucleic acid encodes a protein  
25 which is desirably capable of inducing an immune response to a pathogen. Such a protein may be a protein from rabies virus, human papilloma virus, human immunodeficiency virus (HIV), respiratory syncytial virus (RSV). The vaccine method of the present invention may  
30 also be employed with a tumor-associated protein specific for a selected malignancy. These tumor antigens include viral oncogenes, such as E6 and E7 of human papilloma virus or cellular oncogenes such as mutated ras or p53. Particularly, where the condition is human  
35 immunodeficiency virus (HIV) infection, the protein is

preferably HIV glycoprotein 120 for which sequences are available from GenBank. Where the condition is human papilloma virus infection, the protein is selected from the group consisting of E6, E7 and/or L1 [Seedorf, K. et al, Virology, 145:181-185 (1985)]. Where the condition is respiratory syncytial virus infection, the protein is selected from the group consisting of the glyco- (G) protein and the fusion (F) protein, for which sequences are available from GenBank. In addition to these proteins, other virus-associated proteins are readily available to those of skill in the art. Selection of the heterologous proteins is not a limiting factor in this invention.

In a particularly preferred embodiment, the condition is rabies and the protein is the rabies glycoprotein [see, U.S. Patent No. 4,393,201]. A variety of rabies strains are well known and available from academic and commercial sources, including depositaries such as the American Type Culture Collection, or may be isolated using known techniques. The strain used in the examples below is the Evelyn Rockitniki Abelseth (ERA) strain. However, this invention is not limited by the selection of the rabies strain.

In a preferred embodiment, cDNA encoding the rabies virus glycoprotein is inserted under control of a CMV promoter into the pAdCMV.lacZ (or H5.020CMVlacZ) Ad vector and supplied with the essential genes for infectivity and viral formation in a helper cell line using standard techniques, as described in detail in Example 1. Immunization studies revealed that a single administration of the resulting recombinant replication defective virus conferred complete protection at a relatively low dose following challenge with rabies virus.

## II. Formulation of Vaccine

A recombinant replication defective Ad bearing a gene encoding an immunogenic protein may be administered to a human or veterinary patient, preferably  
5 suspended in a biologically compatible solution or pharmaceutically acceptable delivery vehicle. A suitable vehicle is sterile saline. Other aqueous and non-aqueous isotonic sterile injection solutions and aqueous and non-aqueous sterile suspensions known to be pharmaceutically  
10 acceptable carriers and well known to those of skill in the art may be employed for this purpose.

Optionally, a vaccinal composition of the invention may be formulated to contain other components, including, e.g. adjuvants, stabilizers, pH adjusters,  
15 preservatives and the like. Such components are well known to those of skill in the vaccine art.

## III. Administration of Vaccine

The recombinant, replication defective viruses are administered in an "effective amount", that is, an  
20 amount of recombinant virus that is effective in a route of administration to transfect the desired cells and provide sufficient levels of expression of the selected gene to provide a vaccinal benefit, i.e., protective immunity.

25 Conventional and pharmaceutically acceptable routes of administration include intranasal, intramuscular, intratracheal, subcutaneous, intradermal, rectal, oral and other parental routes of administration. Routes of administration may be combined, if desired, or  
30 adjusted depending upon the immunogen or the disease. For example, in prophylaxis of rabies, the subcutaneous, intratracheal and intranasal routes are preferred. The route of administration primarily will depend on the nature of the disease being treated.

Doses or effective amounts of the recombinant replication defective Ad virus will depend primarily on factors such as the condition, the selected gene, the age, weight and health of the animal, and may thus vary among animals. For example, a prophylactically effective amount or dose of the Ad vaccine is generally in the range of from about 100  $\mu$ l to about 10 ml of saline solution containing concentrations of from about  $1 \times 10^4$  to  $1 \times 10^7$  plaque forming units (pfu) virus/ml. A preferred dose is from about 1 to about 10 ml saline solution at the above concentrations. The levels of immunity of the selected gene can be monitored to determine the need, if any, for boosters.

Currently, when vaccinating against rabies, the preferred dose is about  $10^4$  pfu of the recombinant virus per mouse, preferably suspended in about 0.1 mL saline. Thus, when vaccinating against rabies infection, a larger animal would preferably be administered about a 1 mL dose containing about  $1 \times 10^5$  Adrab.gp pfu suspended in saline. Following an assessment of antibody titers in the serum, optional booster immunizations may be desired.

The following examples illustrate the preferred methods for preparing the vectors and the recombinant viruses used in the vaccine and method of the invention. These examples are illustrative only and do not limit the scope of the invention.

#### Example 1 - Production and Purification of Vectors and Viruses

##### A. Adrab.gp

A recombinant, replication defective adenovirus expressing the rabies virus G protein of the Evelyn Rockitniki Abelseth (ERA) strain of rabies virus [ATCC VR-332; U. S. Patent No. 3,423,505] (ERA) was

constructed as follows. See the flowchart of Figs. 1A to 1D.

The 1650 bp rabies virus G cDNA (nucleotides 1178 to 2827 of SEQ ID NO: 1) was purified from the pSG5rab.gp plasmid [S.R. Burger et al, J. Gen. Virol., 72:359-367 (1991)] upon digestion with *Bgl*II, and blunt-ended with Klenow to supply the G gene. See also United States Patent No. 4,393,201, issued July 12, 1983.

The pAd.CMVlacZ vector [J. Wilson et al, Hum. Gene Ther., 5:501-519 (1994); K. Kozarsky et al, J. Biol. Chem., 269:13695-13702 (1994)], which contains Ad5 m.u. 0-1, followed by the cytomegalovirus (CMV) enhancer/promoter, the beta galactosidase (lacZ) gene, a polyadenylation signal (pA), adenovirus m.u. 9-16 and plasmid sequences from plasmid pAT153 including an origin of replication and ampicillin resistance gene, was completely digested with *Not*I to remove the lacZ gene and provide an ~5.6 kb backbone.

The cDNA encoding the rabies G protein, described above, was inserted into this 5.6 kb fragment via blunt-end cloning to generate pAdCMV.rabgp, which is similar to pAd.CMVlacZ but contains the rabies sequence in place of the lacZ gene. The appropriate orientation of the insert was confirmed by restriction enzyme mapping. pAdCMV.rabgp [SEQ ID NO: 1] contains adenovirus m.u. 0-1 (nucleotides 12 to 364 of SEQ ID NO: 1); followed by a cytomegalovirus enhancer/promoter (nucleotides 382 to 863 of SEQ ID NO: 1); the rabies glycoprotein gene (nucleotides 1178 to 2827 of SEQ ID NO: 1); a polyadenylation signal (nucleotides 2836-3034 of SEQ ID NO: 1); adenovirus m.u. 9-16 (nucleotides 3061 to 5524 of SEQ ID NO: 1); and plasmid sequences from plasmid pAT153 (nucleotides 5525 to 8236 of SEQ ID NO: 1). The remaining nucleotides of SEQ ID NO: 1 are the result of cloning and plasmid construction.

To provide a recombinant virus capable of infecting a cell, the 3' end of the adenovirus sequence was needed to replace the pAT153 plasmid sequences of pAdCMV.rabgp. The plasmid pAdCMV.rabgp was linearized with NheI. The linearized plasmid was co-transfected into 293 packaging cells [ATCC CRL 1573] which contain and express the transforming genes of human adenovirus type 5 to allow replication of the adenovirus [F. L. Graham et al, J. Gen. Virol., 36:59-72 (1977)]. The transfected packaging cells were grown in DMEM with 10% FBS without HEPES buffer in a 5% CO<sub>2</sub> incubator with an E3 deleted Ad5 DNA [Ad5dl7001, a variant that carries a 3 kb deletion between m.u. 78.4 through 86 in the nonessential E3 region (provided by Dr. William Wold, Washington, University, St. Louis, MO)]. This Ad5dl7001 had been digested with a restriction enzyme ClaI to remove the left end, i.e., 917 bp from the 5' end of the adenovirus sequence, rendering the DNA non-infectious.

Following the co-transfection, only products of homologous recombination which occurred between Ad m.u. 9-16 of the pAdCMV.rabgp and the 5' deleted-Ad5dl7001 could produce replicative Ad virus in 293 cells. That is, when homologous recombination occurred, the 3' end of pAd.rabgp from about Ad m.u. 9 to about m.u. 16 and all of the plasmid sequence was swapped with the 3' end of the 5' truncated Ad5dl7001 virus, from about Ad m.u. 9 through m.u. 100.

Several recombinant viral plaques were harvested and tested for expression of the rabies virus G protein as described below. One recombinant, replication defective clone termed Adrab.gp was purified by two rounds of plaque purification and used for further studies and is illustrated schematically in Fig. 1D above.

The recombinant, replication defective Ad Adrab.gp contains Ad5 m.u. 0-1, followed by the CMV enhancer/promoter, the rabies G gene, a pA site, and Ad5 m.u. 9-78.4 and 86-100.

5                   B.    H5.010CMVlacZ

The recombinant replciation defective Ad, H5.010CMVlacZ, is substantially identical to Adrab.gp, except that this virus contains *E. coli lacZ* in place of the rabies G protein and only a partial deletion of E3.

10                   The plasmid pAd.CMVlacZ described above, was linearized with NheI and co-transfected into 293 cells with a partially E3 deleted Ad5 DNA (sub 360 DNA, H5sub360), which had been digested with ClaI to eliminate the sequence of m.u. 83.5 to 85. As above, homologous  
15 recombination, followed by plaing and harvesting produced the resulting recombinant adenovirus, designated H5.010CMVlacZ. This virus contains the sequence from Ad5 m.u. 0-1, followed by the CMV enhancer/promoter, the *Escherichia coli lacZ* gene, a pA site, and Ad5 m.u. 9-  
20 83.5 and 85-100.

C.    Viral Propagation and Purification

The adenoviral recombinants, Adrab.gp H5.010CMVlacZ, and Ad5dl7001, a replication competent adenovirus, on 293 cells for 72 hours. Virus was  
25 recovered on the third round of freeze-thawing. Cell-free supernatants were either used directly or they were further purified by CsCl density centrifugation. Viral stocks were titrated on 293 cells using a plaque assay.

Example 2 - Immunofluorescence and T Cell Studies

30                   To confirm that the Adrab.gp recombinant virus expresses the rabies virus G protein on infected cells in a form recognized by antibodies and cytolytic T cells directed against rabies virus, a series of *in vitro* experiments were performed initially.

A. Indirect Immunofluorescence

To assess the conformation of the G protein as expressed by the Adrab.gp virus, HeLa cells [which had been maintained in Dulbecco's minimal essential medium (DMEM) supplemented with 10% FBS, HEPES buffer and antibiotics in a 10% CO<sub>2</sub> incubator] were infected for 48 hours with 1 pfu of Adrab.gp virus per cell or as a control with H5.020CMVlacZ. Cells were stained 24 hours later by an indirect immunofluorescence assay using three MABs (designated 523-11, 509-6, and 1112-1, and prepared using a 1:100 to 1:1000 dilution of ascitic fluid) to different conformation-dependent binding sites of the rabies virus G protein. The B cell hybridoma cells 509-6, 1112-1, and 523-11 secrete antibodies to different antigenic sites of the rabies virus G protein (509-6 to site I, 1112-1 to site II, and 523-11 to site III [T.J. Wiktor et al, Proc. Natl. Acad. Sci. USA, 75:3938-3945 (1978)]). These hybridoma cells were grown in DMEM supplemented with 10% FBS. Ascetic fluid was prepared in BALB/c mice. The assay was performed as follows.

The HeLa cells were infected for various times with 1 pfu of recombinant adenovirus or with 1 pfu of the vaccinia VRG virus described above per cell in 24-well Costar plates seeded with  $5 \times 10^5$  cells per well. Cells were harvested at varied times after infection by treatment with trypsin and incubated for 60 minutes on ice with the MABs identified above. Cells were washed once with phosphate-buffered saline (PBS) and then incubated with a FITC-labeled goat anti-mouse immunoglobulin (Ig) antibody. Cells were washed and analyzed by a fluorescence activated cell sorter (FACS). Alternatively cells adherent to glass cover slips were stained with the same antibody preparations for subsequent analysis with confocal microscopy.



For all of the antibodies, Adrab.gp virus-infected cells exhibited surface staining with the antibody, while cells infected with the control recombinant virus expressing lacZ were negative.

5                   B. T Cell Proliferation Assay

Further *in vitro* studies showed that the recombinant virus Adrab.gp induced proliferation of a rabies virus G protein specific T helper cell clone in the presence of syngeneic,  $\gamma$ -irradiated splenocytes (Fig. 10 2). In a separate experiment, this T cell clone did not proliferate in the presence of H5.010CMVlacZ (data not shown).

A rabies virus-specific helper T cell clone, obtained from splenocytes of VRG immune C3H/He 15 mice in the inventors' laboratory, was cultured ( $2 \times 10^4$  cells/well) in 96-well round-bottom microtiter plate with  $5 \times 10^5$  irradiated syngeneic C3H/He splenocytes pretreated with different antigen preparations (1, 0.1 and 0.01 pfu Adrab.gp per cell) in DMEM supplemented with 20 2% FBS and  $10^{-6}$  M 2-mercaptoethanol and 10% rat Concanavalin A supernatant as a lymphokine source as described previously [L. Otvos, Jr., Biochim. Biophys. Acta, 1224:68-76 (1994)]. Proliferation of the cloned T cells was assessed 48 hours later by a 6 hour pulse with 25 0.5  $\mu$ Ci of  $^3$ H-thymidine as described in H.C.J. Ertl et al, Eur. J. Immunol., 21:1-10 (1991). Furthermore, mouse fibroblasts infected with the Adrab.gp recombinant virus were rendered susceptible to lysis by rabies virus G protein induced H-2 compatible cytolytic T cells.

30                   Together these *in vitro* experiments demonstrated that Adrab.gp causes expression of the rabies virus G protein in a form that is readily recognized by both rabies virus-specific antibodies and T

cells of the helper and the cytolytic subset. Specifically, Fig. 2 illustrates that Adrab.gp induces proliferation of a rabies virus G protein T helper cell clone in the presence of antigen presenting cells.

5     Example 3 - Immunization Studies

          In the next set of experiments, mice were immunized with the Adrab.gp recombinant virus at several doses using different routes of immunization as follows. Groups of eight to twelve week old outbred ICR [Harlan  
10     Sprague-Dawley (Indianapolis, IN)] or C3H/He mice [The Jackson Laboratories (Bar Harbor, ME)] were injected subcutaneously (s.c.), orally (per os), intranasally (i.n.), or upon anesthesia and surgical exposure of the trachea intratracheally (i.t.), with the recombinant  
15     adenoviruses of the previous examples diluted in 100 to 150  $\mu$ l of saline. VRG [which had been propagated on HeLa cells as described in T. J. Wiktor et al, Proc. Natl. Acad. Sci. USA, 81:7194-7198 (1984)] was given s.c. Mice were bled by retro-orbital puncture in regular intervals  
20     after immunization to assess serum antibody titers.

          The challenge virus standard (CVS)-24 strain of rabies virus, that is antigenically closely related to the ERA strain but shows higher virulence in mice, was derived from brain suspensions of infected newborn ICR  
25     mice [T.J. Wiktor et al, J. Virol., 21:626-633 (1977)]. Mice were challenged with 10 mean lethal doses ( $LD_{50}$ ) of CVS-24 virus given intramuscularly (i.m.) into the masseter muscle; they were observed for the following 3  
30     weeks for symptoms indicative of a rabies virus infection. Mice that developed complete bilateral hind leg paralysis (proceeding death by 24 to 48 hours) were euthanized for humanitarian reasons.

#### A. Virus Neutralizing Antibodies

Groups of ICR mice were immunized in three separate experiments with the different recombinant viruses given at the doses in Table 1 below either i.m., i.n., i.t., or per os. Mice inoculated into the trachea or i.n. were anesthetized prior to vaccination. Mice were bled 10 to 14 days later after a single immunization and serum antibody titers to rabies virus were tested by a neutralization assay. Virus neutralizing antibody (VNA) titers were determined on BHK-21 cells using infectious ERA virus at 1 pfu per cell [B.D. Dietzschold et al, Virology, 161:29-36 (1987)].

Table 1 below illustrates the data expressed as neutralization titers which are the reciprocal of the serum dilution resulting in a 50% reduction in the number of infected cells. Samples were assayed in duplicate in serial 3-fold dilutions starting with a dilution of 1:5. Standard deviations were within 10% for any given experiment.

As illustrated by the results in Table 1, virus given s.c., i.t., or i.n. induced a potent neutralizing antibody response if given at  $10^6$  pfu. Oral immunization with Adrab.gp or systemic immunization with H5.020CMVlacZ failed to induce a measurable antibody response to rabies virus. The antibody responses to different doses of the recombinant replication-defective Adrab.gp were clearly superior to the response induced by the VRG recombinant. For example, the antibody titers of mice inoculated with as little as  $2 \times 10^4$  pfu of Adrab.gp were more than 10 times higher than those of mice infected with  $2 \times 10^6$  pfu of VRG (Table 1).

26

Table 1

**Adrab.gp Recombinant Induces Neutralizing Antibodies  
to Rabies Virus**

5	Vaccine	Dose	Route of Immunizat'n	Time After	VNA titer Immunizat'n
10	Adrab.gp	$2 \times 10^6$	s.c.	day 10	3,645
	Adrab.gp	$2 \times 10^5$	s.c.	day 10	405
	Adrab.gp	$2 \times 10^4$	s.c.	day 10	405
	VRG	$2 \times 10^6$	s.c.	day 10	45
	VRG	$2 \times 10^5$	s.c.	day 10	15
	VRG	$2 \times 10^4$	s.c.	day 10	5
	None	-	-	day 10	<5
	Adrab.gp	$10^4$	s.c.	day 14	1,215
	Adrab.gp	$10^3$	s.c.	day 14	405
	Adrab.gp	$10^2$	s.c.	day 14	<5
15	Adrab.gp	$10^6$	i.n.	day 14	1,215
	Adrab.gp	$10^6$	i.t.	day 14	3,645
	Adrab.gp	$10^6$	per os	day 14	<5
	None	-	-		<5

To ensure that the antibody response was caused by infection recombinant virus rather than by G protein fragments contaminating the virus-containing tissue culture supernatant used for immunization, mice were vaccinated with an equal dose of PFUs of unpurified and gradient purified recombinant adenovirus. Both groups of mice developed identical virus neutralizing antibody titers.

**B. Cell-mediated Cytolysis**

In addition to neutralizing antibodies, mice inoculated s.c. with Adrab.gp virus developed rabies virus G protein-specific cytolytic T cells able to kill H-2 compatible L929 target cells stably transfected with a plasmid vector expressing the rabies virus G protein under the control of the SV40 early promoter [Z. Q. Xiang et al, J. Virol. Meth., 47:103-116 (1994)].

L929 mouse fibroblasts were maintained in Dulbecco's minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS), HEPES buffer and antibiotics in a 10% CO<sub>2</sub> incubator. L929 cells stably  
5 transfected with pSG5rab.gp [S.R. Burger et al, cited above], expressing the rabies virus G protein as well as L929 cells transfected with pSV2neo [ATCC Accession No. 37149] were maintained in 10% DMEM supplemented with 10% FBS. These cell lines used as target cells for cell-  
10 mediated cytotoxicity assays have been described in detail previously [Z.Q. Xiang et al, J. Virol. Meth., 47:103-116 (1994)].

Briefly, splenocytes were harvested from immunized C3H/He mice. Single cells were prepared and  
15 incubated at  $6 \times 10^6$  cells per well with 1 pfu per cell of the Adrab.gp recombinant virus in 1.6 ml of DMEM supplemented with  $10^{-6}$  M 2-mercaptoethanol and 2% FBS for 5 days in a humidified 10% CO<sub>2</sub> incubator. The effector cells were then co-cultured with <sup>51</sup>Cr-labeled L929 cells  
20 expressing the rabies virus G protein upon stable transfection with the pSG5rab.gp vector at varied effector-to-target cells ratios. To assess spontaneous release, <sup>51</sup>Cr-labeled target cells were incubated with medium; to determine maximal release target cells were  
25 co-cultured with 10% sodium dodecyl sulfate. Cell-free supernatants were harvested 4 hours later and radioactivity was measured. Percentage of specific lysis was calculated by using the formula [Y. Yang et al, Immunity, 1:433-442 (1994)]:

30 
$$100 \times \frac{(\text{Release in presence of effectors} - \text{spontaneous release})}{(\text{Maximal release} - \text{spontaneous release})}$$

The results are illustrated graphically in Fig. 3A, which illustrates that the Adrab.gp construct  
35 induces cytotoxic T cells to the rabies virus G protein.

See, also the results of Fig. 3B, in which lymphocytes were tested at different E:T ratios on an L929 cell line transfected with Adrab.gp or a neomycin expressing control.

5     Example 4 - Challenge Studies

Four different experiments were conducted in which mice, immunized as described in Example 3A above, were challenged with 10 LD<sub>50</sub> of rabies virus. Briefly, mice immunized with the Adrab.gp or the VRG recombinant virus were challenged 2 to 5 weeks after immunization with 10 LD<sub>50</sub> of the virulent CVS-24 strain of rabies virus given i.m. into the masseter muscle. Mice that subsequently developed complete bilateral hind leg paralysis indicative of a terminal rabies virus infection were euthanized for humanitarian reasons. Survivors were observed for a total of 21 days.

The results are illustrated in Table 2 below. Mice immunized with Adrab.gp i.m., i.t., or i.n. using doses ranging from 10<sup>4</sup> to 2 x 10<sup>6</sup> pfu were fully protected against infection; 87% of mice inoculated with 10<sup>3</sup> pfu were protected. All mice immunized with only 10<sup>2</sup> pfu of the recombinant adenovirus or inoculated with the H5.020CMVlacZ control virus (2 x 10<sup>6</sup> pfu) or with Adrab.gp per os developed a fatal rabies virus encephalitis within 10 days after infection. Mice vaccinated with VRG showed partial protection; the group receiving the highest dose, i.e., 2 x 10<sup>6</sup> pfu, had a mortality rate above 50% raising to ~90% in mice inoculated with 2 x 10<sup>4</sup> pfu of VRG.

Table 2

**Adrab.gp Recombinant Virus Induces Protective Immunity to  
Challenge with Rabies Virus**

5	Vaccine	Dose	Route of immunization	% mortality
	Adrab.gp	$2 \times 10^6$	s.c.	0
	H5.010CMVlacZ	$2 \times 10^6$	s.c.	90
10	Adrab.gp	$2 \times 10^6$	s.c.	0
	Adrab.gp	$2 \times 10^5$	s.c.	0
	Adrab.gp	$2 \times 10^4$	s.c.	0
	VRG	$2 \times 10^6$	s.c.	56
	VRG	$2 \times 10^5$	s.c.	71
15	VRG	$2 \times 10^4$	s.c.	86
	None	-	-	100
	Adrab.gp	$10^4$	s.c.	0
	Adrab.gp	$10^3$	s.c.	13
	Adrab.gp	$10^2$	s.c.	100
20	None	-	-	100
	Adrab.gp	$10^6$	i.n.	0
	Adrab.gp	$10^6$	i.t.	0
	Adrab.gp	$10^6$	per os	100
25	None	-	-	100

**Example 5 - Comparison Studies**

The relationship between the magnitude of an immune response and the amount of antigen available to induce naive T and B cells was studied. As determined by immunofluorescence and subsequent analysis by FACS (Figs. 4A-4L), both the VRG and the Adrab.gp recombinants express comparable levels of the rabies virus G protein but the kinetics of expression are different. Cells infected with the VRG virus express high levels of G protein within 12 hours after infection; these levels increased over the next day. By 60 hours the VRG virus

has completely lysed a cell population infected with ~1 pfu of virus per cell.

The same cell line infected with 1 pfu of Adrab.gp per cell shows low expression of the rabies virus G protein on day 1. The level of expression increases until days 3 to 4 after infection and then reaches plateau levels (data shown for days 1 to 3 in Fig. 4A through Fig. 4L). The replication-defective recombinant adenoviruses are non-lytic and maintain stable infection and expression of virus-encoded proteins for extended periods of time. In tissue culture, expression has been shown for 7 days *in vivo*; using the H5.010CMVlacZ recombinant virus, stable levels of expression were demonstrated in immunocompromised mice for 10 months.

A non-lytic virus, e.g., the recombinant replication defective adenovirus, that expresses antigens for prolonged periods of time might thus be more immunogenic compared to a replicating agent that causes death of the infected cells within 24 to 48 hours, e.g., vaccinia.

To substantiate this hypothesis, the inventors compared the immune response to rabies proteins upon immunization of mice with a replication-defective E1 deleted adenovirus and a replication-competent adenovirus. Both adenoviruses were of the human strain 5 and both were deleted in E3. These recombinant viruses were tested by enzyme linked immunoadsorbent assay (ELISA) (Figs. 5A and 5B). The ELISAs were conducted in 96-well microtiter plates coated with 0.1 to 0.2  $\mu$ g per well of ERA-BPL virus or 1-2  $\mu$ g per well of purified H5.010CMVlacZ virus, using an alkaline phosphatase conjugated goat anti-mouse Ig as second antibody as described in detail in Xiang and Ertl, Virus Res., 24:297-314 (1992). As shown in Figs. 5A and 5B, the



antibody response to the E1 deleted Adrab.gp virus (solid box) was superior to that of a replication competent Ad virus (open box). This supports the position that long-term expression of viral antigens by a non-lytic virus  
5 can induce stronger immune response compared to short-term expression by a replication-competent agent. Figs. 5A and 5B illustrate that expression of E1 causes a reduction in the antibody response to adenovirus.

These studies demonstrate that the recombinant  
10 replication-defective adenovirus used in the present invention shows higher immunogenicity compared to a replication-competent adenovirus. Without wishing to be bound by theory, it is believed that the length of expression of the antigen plays a role in induction of  
15 the immune response. In similar studies comparing the replication defective adenovirus vaccine to the VRG vaccine, the Ad vaccine expresses the rabies antigen longer than the VRG recombinant virus vaccine.

#### Example 6 - Further Comparative Studies

20 The following study was performed to test if pre-existing immunity to adenoviral proteins interferes with stimulation of a rabies G protein-specific immune response to the Adrab.gp construct. Groups of C3H/He mice were immunized with  $10^5$  or  $10^6$  pfu of a replication-  
25 competent adenovirus human serotype 5 that had been deleted of the E3 gene. Mice were injected 4 weeks later with  $10^6$  pfu of Adrab.gp. Control mice were only injected with Adrab.gp ( $10^6$  pfu). Mice were bled 12 days later and neutralizing antibody titers were determined  
30 (Table 3).

Table 3

The Effect of Pre-Existing Immunity to Adenovirus on the Rabies VNA Response to the Adrab.gp Vaccine

5	Pre-immunization Titer	Immunization	VNA
10	None	10 <sup>6</sup> pfu Adrab.gp	3.645
	10 <sup>5</sup> pfu Ad5d17001	10 <sup>6</sup> pfu Adrab.gp	3.645
	10 <sup>6</sup> pfu Ad517001	10 <sup>6</sup> pfu Adrab.gp	1.215
	None	None	<5

Mice pre-immunized with adenovirus developed VNA to rabies virus upon booster immunization with the Adrab.gp construct. Titers were equivalent, or marginally lower, when compared to those in control mice that had only received Adrab.gp, indicating that antibodies to adenoviruses only marginally inhibit the B cell response to proteins expressed by adenovirus recombinants. When tested in comparison to a reference serum provided by the World Health Organization, sera from pre-immune (both doses of adenovirus) or naive mice were shown to have titers of 40 IU to rabies virus. Protection to rabies virus is correlated to antibody titers and 2 IU are considered sufficient to protect against a severe challenge. Pre-immunity to adenovirus does, thus, not impair the ability of the Adrab.gp vaccine to elicit protective immunity.

Similar data were obtained for the stimulation of cytolytic T cells to rabies virus-infected cells, pre-immune animals showed somewhat lower lysis compared to the control group (see Figs. 6A and 6B). Figs. 6A and 6B illustrate that the cytolytic T cell response to rabies virus G protein expressing target cells upon immunization with Adrab.gp is only slightly reduced in animals immune

to adenovirus. Nevertheless, adenovirus-immune mice still developed significant T cell responses to the rabies virus G protein upon immunization with Adrab.gp.

Example 7 - Additional Challenge Studies

5           In this experiment the kinetic of the induction of protective immunity upon vaccination was tested with the Adrab.gp virus. Vaccination to rabies virus is in general given post-exposure, hence it is crucial for the vaccine to induce a rapid immune response before the  
10 rabies virus has reached the central nervous system.

          Mice were immunized with  $10^6$  PFU of Adrab.gp s.c. Immunized mice were challenged 3 (◇), 7 (□), and 10 (■) days after vaccination with 10 LD<sub>50</sub> of rabies virus given i.m. Naive mice (X) served as controls. Mice were  
15 observed for four weeks to record mortality. As shown in Fig. 7, mice vaccinated with Adrab.gp virus 10 days previously were completely protected; while more than half of the animals were protected as early as seven days after a single injection. Mice vaccinated three days  
20 before challenge succumbed to the infection.

          Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. Such modifications and alterations to  
25 the compositions and processes of the present invention are believed to be encompassed in the scope of the claims appended hereto.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Wistar Institute of Anatomy and Biology  
Trustees of the University of Pennsylvania  
Ertl, Hildegund C.J.  
Wilson, James M.
- (ii) TITLE OF INVENTION: A Replication-Defective  
Adenovirus Human Type 5  
Recombinant as a Vaccine Carrier
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Howson and Howson
  - (B) STREET: Spring House Corporate Cntr, PO Box 457
  - (C) CITY: Spring House
  - (D) STATE: Pennsylvania
  - (E) COUNTRY: USA
  - (F) ZIP: 19477
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: WO
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 08/461,837
  - (B) FILING DATE: 05-JUN-1995
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 60/000,078
  - (B) FILING DATE: 08-JUN-1995
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Bak, Mary E.
  - (B) REGISTRATION NUMBER: 31,215
  - (C) REFERENCE/DOCKET NUMBER: UPNH1290APCT
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 215-540-9200
  - (B) TELEFAX: 215-540-5818

35

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8236 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: not relevant

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1185..2756

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAATTCGCTA GCATCATCAA TAATATACCT TATTTTGGAT TGAAGCCAAT	50
ATGATAATGA GGGGGTGGAG TTTGTGACGT GGCGCGGGGC GTGGGAACGG	100
GGCGGGTGAC GTAGTAGTGT GGCGGAAGTG TGATGTTGCA AGTGTGGCGG	150
AACACATGTA AGCGACGGAT GTGGCAAAAG TGACGTTTTT GGTGTGCGCC	200
GGTGTACACA GGAAGTGACA ATTTTCGCGC GGTTTTAGGC GGATGTTGTA	250
GTAAATTTGG GCGTAACCGA GTAAGATTTG GCCATTTTCG CGGGAAAACT	300
GAATAAGAGG AAGTGAAATC TGAATAATTT TGTGTTACTC ATAGCGCGTA	350
ATATTTGTCT AGGGAGATCA GCCTGCAGGT CGTTACATAA CTTACGGTAA	400
ATGGCCCCGCC TGGCTGACCG CCCAACGACC CCCGCCCAT T GACGTCAATA	450
ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC ATTGACGTCA	500
ATGGGTGGAG TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT	550
ATCATATGCC AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC	600
GCCTGGCATT ATGCCCAGTA CATGACCTTA TGGGACTTTC C TACTTGGCA	650
GTACATCTAC GTATTAGTCA TCGCTATTAC CATGGTGATG CGGTTTTGGC	700
AGTACATCAA TGGGCGTGGA TAGCGGTTTG ACTCACGGGG ATTTCCAAGT	750
CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC AAAATCAACG	800
GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG	850
GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCG TTTAGTGAAC	900

36

CGTCAGATCG	CCTGGAGACG	CCATCCACGC	TGTTTTGACC	TCCATAGAAG	950
ACACCGGGAC	CGATCCAGCC	TCCGGACTCT	AGAGGATCCG	GTA	1000
AACTGAAAAA	CCAGAAAGTT	AACTGGTAAG	TTTAGTCTTT	TTGTCTTTTA	1050
TTTCAGGTCC	CGGATCCGGT	GGTGGTGCAA	ATCAAAGAAC	TGCTCCTCAG	1100
TGGATGTTGC	CTTTACTTCT	AGGCCTGTAC	GGAAGTGTTA	CTTCTGCTCT	1150
AAAAGCTGCG	GAATTGTACC	CGCGGCCAGG	AAAG ATG GTT CCT CAG	Met Val Pro Gln	1196
			1		
GCT CTC CTG TTT GTA CCC CTT CTG GTT TTT CCA TTG TGT TTT	1238				
Ala Leu Leu Phe Val Pro Leu Leu Val Phe Pro Leu Cys Phe					
5 10 15					
GGG AAA TTC CCT ATT TAC ACG ATA CTA GAC AAG CTT GGT CCC	1280				
Gly Lys Phe Pro Ile Tyr Thr Ile Leu Asp Lys Leu Gly Pro					
20 25 30					
TGG AGC CCG ATT GAC ATA CAT CAC CTC AGC TGC CCA AAC AAT	1322				
Trp Ser Pro Ile Asp Ile His His Leu Ser Cys Pro Asn Asn					
35 40 45					
TTG GTA GTG GAG GAC GAA GGA TGC ACC AAC CTG TCA GGG TTC	1364				
Leu Val Val Glu Asp Glu Gly Cys Thr Asn Leu Ser Gly Phe					
50 55 60					
TCC TAC ATG GAA CTT AAA GTT GGA TAC ATC TTA GCC ATA AAA	1406				
Ser Tyr Met Glu Leu Lys Val Gly Tyr Ile Leu Ala Ile Lys					
65 70					
ATG AAC GGG TTC ACT TGC ACA GGC GTT GTG ACG GAG GCT GAA	1448				
Met Asn Gly Phe Thr Cys Thr Gly Val Val Thr Glu Ala Glu					
75 80 85					
ACC TAC ACT AAC TTC GTT GGT TAT GTC ACA ACC ACG TTC AAA	1490				
Thr Tyr Thr Asn Phe Val Gly Tyr Val Thr Thr Thr Phe Lys					
90 95 100					
AGA AAG CAT TTC CGC CCA ACA CCA GAT GCA TGT AGA GCC GCG	1532				
Arg Lys His Phe Arg Pro Thr Pro Asp Ala Cys Arg Ala Ala					
105 110 115					
TAC AAC TGG AAG ATG GCC GGT GAC CCC AGA TAT GAA GAG TCT	1574				
Tyr Asn Trp Lys Met Ala Gly Asp Pro Arg Tyr Glu Glu Ser					
120 125 130					

37

CTA	CAC	AAT	CCG	TAC	CCT	GAC	TAC	CGC	TGG	CTT	CGA	ACT	GTA	1616
Leu	His	Asn	Pro	Tyr	Pro	Asp	Tyr	Arg	Trp	Leu	Arg	Thr	Val	
				135					140					
AAA	ACC	ACC	AAG	GAG	TCT	CTC	GTT	ATC	ATA	TCT	CCA	AGT	GTA	1658
Lys	Thr	Thr	Lys	Glu	Ser	Leu	Val	Ile	Ile	Ser	Pro	Ser	Val	
145				150						155				
GCA	GAT	TTG	GAC	CCA	TAT	GAC	AGA	TCC	CTT	CAC	TCG	AGG	GTC	1700
Ala	Asp	Leu	Asp	Pro	Tyr	Asp	Arg	Ser	Leu	His	Ser	Arg	Val	
160						165					170			
TTC	CCT	AGC	GGG	AAG	TGC	TCA	GGA	GTA	GCG	GTG	TCT	TCT	ACC	1742
Phe	Pro	Ser	Gly	Lys	Cys	Ser	Gly	Val	Ala	Val	Ser	Ser	Thr	
		175					180					185		
TAC	TGC	TCC	ACT	AAC	CAC	GAT	TAC	ACC	ATT	TGG	ATG	CCC	GAG	1784
Tyr	Cys	Ser	Thr	Asn	His	Asp	Tyr	Thr	Ile	Trp	Met	Pro	Glu	
			190					195					200	
AAT	CCG	AGA	CTA	GGG	ATG	TCT	TGT	GAC	ATT	TTT	ACC	AAT	AGT	1826
Asn	Pro	Arg	Leu	Gly	Met	Ser	Cys	Asp	Ile	Phe	Thr	Asn	Ser	
				205					210					
AGA	GGG	AAG	AGA	GCA	TCC	AAA	GGG	AGT	GAG	ACT	TGC	GGC	TTT	1868
Arg	Gly	Lys	Arg	Ala	Ser	Lys	Gly	Ser	Glu	Thr	Cys	Gly	Phe	
215					220					225				
GTA	GAT	GAA	AGA	GGC	CTA	TAT	AAG	TCT	TTA	AAA	GGA	GCA	TGC	1910
Val	Asp	Glu	Arg	Gly	Leu	Tyr	Lys	Ser	Leu	Lys	Gly	Ala	Cys	
230						235					240			
AAA	CTC	AAG	TTA	TGT	GGA	GTT	CTA	GGA	CTT	AGA	CTT	ATG	GAT	1952
Lys	Leu	Lys	Leu	Cys	Gly	Val	Leu	Gly	Leu	Arg	Leu	Met	Asp	
		245					250					255		
GGA	ACA	TGG	GTC	GCG	ATG	CAA	ACA	TCA	AAT	GAA	ACC	AAA	TGG	1994
Gly	Thr	Trp	Val	Ala	Met	Gln	Thr	Ser	Asn	Glu	Thr	Lys	Trp	
			260					265					270	
TGC	CCT	CCC	GAT	CAG	TTG	GTG	AAC	CTG	CAC	GAC	TTT	CGC	TCA	2036
Cys	Pro	Pro	Asp	Gln	Leu	Val	Asn	Leu	His	Asp	Phe	Arg	Ser	
				275					280					
GAC	GAA	ATT	GAG	CAC	CTT	GTT	GTA	GAG	GAG	TTG	GTC	AGG	AAG	2078
Asp	Glu	Ile	Glu	His	Leu	Val	Val	Glu	Glu	Leu	Val	Arg	Lys	
285					290					295				
AGA	GAG	GAG	TGT	CTG	GAT	GCA	CTA	GAG	TCC	ATC	ATG	ACA	ACC	2120
Arg	Glu	Glu	Cys	Leu	Asp	Ala	Leu	Glu	Ser	Ile	Met	Thr	Thr	
						305					310			

38

AAG TCA GTG AGT TTC AGA CGT CTC AGT CAT TTA AGA AAA CTT	2162
Lys Ser Val Ser Phe Arg Arg Leu Ser His Leu Arg Lys Leu	
315 320 325	
GTC CCT GGG TTT GGA AAA GCA TAT ACC ATA TTC AAC AAG ACC	2204
Val Pro Gly Phe Gly Lys Ala Tyr Thr Ile Phe Asn Lys Thr	
330 335 340	
TTG ATG GAA GCC GAT GCT CAC TAC AAG TCA GTC AGA ACT TGG	2246
Leu Met Glu Ala Asp Ala His Tyr Lys Ser Val Arg Thr Trp	
345 350	
AAT GAG ATC CTC CCT TCA AAA GGG TGT TTA AGA GTT GGG GGG	2288
Asn Glu Ile Leu Pro Ser Lys Gly Cys Leu Arg Val Gly Gly	
355 360 365	
AGG TGT CAT CCT CAT GTG AAC GGG GTG TTT TTC AAT GGT ATA	2330
Arg Cys His Pro His Val Asn Gly Val Phe Phe Asn Gly Ile	
370 375 380	
ATA TTA GGA CCT GAC GGC AAT GTC TTA ATC CCA GAG ATG CAA	2372
Ile Leu Gly Pro Asp Gly Asn Val Leu Ile Pro Glu Met Gln	
385 390 395	
TCA TCC CTC CTC CAG CAA CAT ATG GAG TTG TTG GAA TCC TCG	2414
Ser Ser Leu Leu Gln Gln His Met Glu Leu Leu Glu Ser Ser	
400 405 410	
GTT ATC CCC CTT GTG CAC CCC CTG GCA GAC CCG TCT ACC GTT	2456
Val Ile Pro Leu Val His Pro Leu Ala Asp Pro Ser Thr Val	
415 420	
TTC AAG GAC GGT GAC GAG GCT GAG GAT TTT GTT GAA GTT CAC	2498
Phe Lys Asp Gly Asp Glu Ala Glu Asp Phe Val Glu Val His	
425 430 435	
CTT CCC GAT GTG CAC AAT CAG GTC TCA GGA GTT GAC TTG GGT	2540
Leu Pro Asp Val His Asn Gln Val Ser Gly Val Asp Leu Gly	
440 445 450	
CTC CCG AAC TGG GGG AAG TAT GTA TTA CTG AGT GCA GGG GCC	2582
Leu Pro Asn Trp Gly Lys Tyr Val Leu Leu Ser Ala Gly Ala	
455 460 465	
CTG ACT GCC TTG ATG TTG ATA ATT TTC CTG ATG ACA TGT TGT	2624
Leu Thr Ala Leu Met Leu Ile Ile Phe Leu Met Thr Cys Cys	
470 475 480	
AGA AGA GTC AAT CGA TCA GAA CCT ACG CAA CAC AAT CTC AGA	2666
Arg Arg Val Asn Arg Ser Glu Pro Thr Gln His Asn Leu Arg	
485 490	



39

GGG ACA GGG AGG GAG GTG TCA GTC ACT CCC CAA AGC GGG AAG	2708
Gly Thr Gly Arg Glu Val Ser Val Thr Pro Gln Ser Gly Lys	
495 500 505	
ATC ATA TCT TCA TGG GAA TCA CAC AAG AGT GGG GGT GAG ACC	2750
Ile Ile Ser Ser Trp Glu Ser His Lys Ser Gly Gly Glu Thr	
510 515 520	
AGA CTG TGAGGACTGG CCGTCCTTTC AACGATCCAA GTCCTGAAGA	2796
Arg Leu	
TCACCTCCCC TTGGGGGGTT CTTTTTAAAA AGGCCGCGGG GATCCAGACA	2846
TGATAAGATA CATTGATGAG TTTGGACAAA CCACAAC TAG AATGCAGTGA	2896
AAAAAATGCT TTATTTGTGA AATTTGTGAT GCTATTGCTT TATTTGTAAC	2946
CATTATAAGC TGCAATAAAC AAGTTAACAA CAACAATTGC ATTCATTTTA	2996
TGTTTCAGGT TCAGGGGGAG GTGTGGGAGG TTTTTCGGA TCCTCTAGAG	3046
TCGACCTGCA GGCTGATCTG GAAGGTGCTG AGGTACGATG AGACCCGCAC	3096
CAGGTGCAGA CCCTGCGAGT GTGGCGGTAA ACATATTAGG AACCAGCCTG	3146
TGATGCTGGA TGTGACCGAG GAGCTGAGGC CCGATCACTT GGTGCTGGCC	3196
TGCACCCGCG CTGAGTTTGG CTCTAGCGAT GAAGATACAG ATTGAGGTAC	3246
TGAAATGTGT GGGCGTGGCT TAAGGGTGGG AAAGAATATA TAAGGTGGGG	3296
GTCTTATGTA GTTTTGTATC TGTTTTCAG CAGCCGCCGC CGCCATGAGC	3346
ACCAACTCGT TTGATGGAAG CATTGTGAGC TCATATTTGA CAACGCGCAT	3396
GCCCCCATGG GCCGGGGTGC GTCAGAATGT GATGGGCTCC AGCATTGATG	3446
GTCGCCCCGT CCTGCCCCGA AACTCTACTA CCTTGACCTA CGAGACCGTG	3496
TCTGGAACGC CGTTGGAGAC TGCAGCCTCC GCCGCCGCTT CAGCCGCTGC	3546
AGCCACCGCC CGCGGGATTG TGA CTGACTT TGCTTTCCTG AGCCCGCTTG	3596
CAAGCAGTGC AGCTTCCCGT TCATCCGCCC GCGATGACAA GTTGACGGCT	3646
CTTTTGGCAC AATTGGATTC TTTGACCCGG GAACTTAATG TCGTTTCTCA	3696
GCAGCTGTTG GATCTGCGCC AGCAGGTTTC TGCCCTGAAG GCTTCCTCCC	3746
CTCCCAATGC GGTTTAAAAC ATAAATAAAA AACCAGACTC TGTTTGGATT	3796

TGGATCAAGC	AAGTGTCTTG	CTGTCTTTAT	TTAGGGGTTT	TGCGCGCGCG	3846
GTAGGCCCCG	GACCAGCGGT	CTCGGTCGTT	GAGGGTCCTG	TGTATTTTTT	3896
CCAGGACGTG	GTAAAGGTGA	CTCTGGATGT	TCAGATACAT	GGGCATAAGC	3946
CCGTCTCTGG	GGTGGAGGTA	GCACCACTGC	AGAGCTTCAT	GCTGCGGGGT	3996
GGTGTGTAG	ATGATCCAGT	CGTAGCAGGA	GCGCTGGGCG	TGGTGCCTAA	4046
AAATGTCTTT	CAGTAGCAAG	CTGATTGCCA	GGGGCAGGCC	CTTGGTGTAA	4096
GTGTTTACAA	AGCGGTTAAG	CTGGGATGGG	TGCATACGTG	GGGATATGAG	4146
ATGCATCTTG	GACTGTATTT	TTAGGTTGGC	TATGTTCCCA	GCCATATCCC	4196
TCCGGGGATT	CATGTTGTGC	AGAACCACCA	GCACAGTGTA	TCCGGTGCAC	4246
TTGGGAAATT	TGTCATGTAG	CTTAGAAGGA	AATGCGTGGA	AGAAGTTGGA	4296
GACGCCCTTG	TGACCTCAA	GATTTTCCAT	GCATTCTGTC	ATAATGATGG	4346
CAATGGGCCC	ACGGGCGGCG	GCCTGGGCGA	AGATATTTCT	GGGATCACTA	4396
ACGTCATAGT	TGTGTTCCAG	GATGAGATCG	TCATAGGCCA	TTTTTACAAA	4446
GCGCGGGCGG	AGGGTGCCAG	ACTGCGGTAT	AATGGTTCCA	TCCGGCCCAG	4496
GGGCGTAGTT	ACCCTCACAG	ATTTGCATTT	CCCACGCTTT	GAGTTCAGAT	4546
GGGGGGATCA	TGTCTACCTG	CGGGGCGATG	AAGAAAACGG	TTTCCGGGGT	4596
AGGGGAGATC	AGCTGGGAAG	AAAGCAGGTT	CCTGAGCAGC	TGCGACTTAC	4646
CGCAGCCGGT	GGGCCCCGTA	ATCACACCTA	TTACCGGGTG	CAACTGGTAG	4696
TTAAGAGAGC	TGCAGCTGCC	GTCATCCCTG	AGCAGGGGGG	CCACTTCGTT	4746
AAGCATGTCC	CTGACTCGCA	TGTTTTCCCT	GACCAAATCC	GCCAGAAGGC	4796
GCTCGCCGCC	CAGCGATAGC	AGTTCTTGCA	AGGAAGCAAA	GTTTTTCAAC	4846
GGTTTGAGAC	CGTCCGCCGT	AGGCATGCTT	TTGAGCGTTT	GACCAAGCAG	4896
TTCCAGGCGG	TCCCACAGCT	CGGTCACCTG	CTCTACGGCA	TCTCGATCCA	4946
GCATATCTCC	TCGTTTCGCG	GGTTGGGGCG	GCTTTCGCTG	TACGGCAGTA	4996
GTCGGTGCTC	GTCCAGACGG	GCCAGGGTCA	TGTCTTTCCA	CGGGCGCAGG	5046
GTCCTCGTCA	GCGTAGTCTG	GGTCACGGTG	AAGGGGTGCG	CTCCGGGCTG	5096

CGCGCTGGCC	AGGGTGC	CTGAGGCTGGT	CCTGCTGGTG	CTGAAGCGCT	5146
GCCGGTCTTC	GCCCTGCGCG	TCGGCCAGGT	AGCATTTGAC	CATGGTGTCA	5196
TAGTCCAGCC	CCTCCGCGGC	GTGGCCCTTG	GCGCGCAGCT	TGCCCTTGGA	5246
GGAGGCGCCG	CACGAGGGGC	AGTGCAGACT	TTTGAGGGCG	TAGAGCTTGG	5296
GCGCGAGAAA	TACCGATTCC	GGGGAGTAGG	CATCCGCGCC	GCAGGCCCCG	5346
CAGACGGTCT	CGCATTCCAC	GAGCCAGGTG	AGCTCTGGCC	GTTCCGGGGTC	5396
AAAAACCAGG	TTTCCCCCAT	GCTTTTTGAT	GCGTTTCTTA	CCTCTGGTTT	5446
CCATGAGCCG	GTGTCCACGC	TCGGTGACGA	AAAGGCTGTC	CGTGTCCCCG	5496
TATACAGACT	TGAGAGGCCT	GTCCTCGACC	GATGCCCTTG	AGAGCCTTCA	5546
ACCCAGTCAG	CTCCTTCCGG	TGGGCGCGGG	GCATGACTAT	CGTCGCCGCA	5596
CTTATGACTG	TCTTCTTTAT	CATGCAACTC	GTAGGACAGG	TGCCGGCAGC	5646
GCTCTGGGTC	ATTTTCGGCG	AGGACCGCTT	TCGCTGGAGC	GCGACGATGA	5696
TCGGCCTGTC	GCTTGCGGTA	TTCGGAATCT	TGCACGCCCT	CGCTCAAGCC	5746
TTCGTCACTG	GTCCCGCCAC	CAAACGTTTC	GGCGAGAAGC	AGGCCATTAT	5796
CGCCGGCATG	GCGGCCGACG	CGCTGGGCTA	CGTCTTGCTG	GCGTTCGCGA	5846
CGCGAGGCTG	GATGGCCTTC	CCCATTATGA	TTCTTCTCGC	TTCCGGCGGC	5896
ATCGGGATGC	CCGCGTTGCA	GGCCATGCTG	TCCAGGCAGG	TAGATGACGA	5946
CCATCAGGGA	CAGCTTCAAG	GATCGCTCGC	GGCTCTTACC	AGCCTAACTT	5996
CGATCACTGG	ACCGCTGATC	GTCACGGCGA	TTTATGCCGC	CTCGGCGAGC	6046
ACATGGAACG	GGTTGGCATG	GATTGTAGGC	GCCGCCCTAT	ACCTTGTCTG	6096
CCTCCCCGCG	TTGCGTCGCG	GTGCATGGAG	CCGGGCCACC	TCGACCTGAA	6146
TGGAAGCCGG	CGGCACCTCG	CTAACGGATT	CACCACTCCA	AGAATTGGAG	6196
CCAATCAATT	CTTGCGGAGA	ACTGTGAATG	CGCAAACCAA	CCCTTGGCAG	6246
AACATATCCA	TCGCGTCCGC	CATCTCCAGC	AGCCGCACGC	GGCGCATCTC	6296
GGGCAGCGTT	GGGTCCTGGC	CACGGGTGCG	CATGATCGTG	CTCCTGTCGT	6346
TGAGGACCCG	GCTAGGCTGG	CGGGGTTGCC	TTACTGGTTA	GCAGAATGAA	6396

TCACCGATAC GCGAGCGAAC GTGAAGCGAC TGCTGCTGCA AAACGTCTGC	6446
GACCTGAGCA ACAACATGAA TGGTCTTCGG TTTCCGTGTT TCGTAAAGTC	6496
TGGAAACGCG GAAGTCAGCG CCCTGCACCA TTATGTTCCG GATCTGCATC	6546
GCAGGATGCT GCTGGCTACC CTGTGGAACA CCTACATCTG TATTAACGAA	6596
GCCTTTCTCA ATGCTCACGC TGTAGGTATC TCAGTTCGGT GTAGGTCGTT	6646
CGCTCCAAGC TGGGCTGTGT GCACGAACCC CCCGTTTCAGC CCGACCGCTG	6696
CGCCTTATCC GGTAACATATC GTCTTGAGTC CAACCCGGTA AGACACGACT	6746
TATCGCCACT GGCAGCAGCC ACTGGTAACA GGATTAGCAG AGCGAGGTAT	6796
GTAGGCGGTG CTACAGAGTT CTTGAAGTGG TGGCCTAACT ACGGCTACAC	6846
TAGAAGGACA GTATTTGGTA TCTGCGCTCT GCTGAAGCCA GTTACCTTCG	6896
GAAAAAGAGT TGGTAGCTCT TGATCCGGCA AACAAACCAC CGCTGGTAGC	6946
GGTGGTTTTT TTGTTTGCAA GCAGCAGATT ACGCGCAGAA AAAAAGGATC	6996
TCAAGAAGAT CCTTTGATCT TTTCTACGGG GTCTGACGCT CAGTGAACG	7046
AAACTCAGC TTAAGGGATT TTGGTCATGA GATTATCAAA AAGGATCTTC	7096
ACCTAGATCC TTTTAAATTA AAAATGAAGT TTTAAATCAA TCTAAAGTAT	7146
ATATGAGTAA ACTTGGTCTG ACAGTTACCA ATGCTTAATC AGTGAGGCAC	7196
CTATCTCAGC GATCTGTCTA TTTTCGTTTCAT CCATAGTTGC CTGACTCCCC	7246
GTCGTGTAGA TAACTACGAT ACGGGAGGGC TTACCATCTG GCCCCAGTGC	7296
TGCAATGATA CCGCGAGACC CACGCTCACC GGCTCCAGAT TTATCAGCAA	7346
TAAACCAGCC AGCCGGAAGG GCCGAGCGCA GAAGTGGTCC TGCAACTTTA	7396
TCCGCCTCCA TCCAGTCTAT TAATTGTTGC CGGGAAGCTA GAGTAAGTAG	7446
TTCGCCAGTT AATAGTTTGC GCAACGTTGT TGCCATTGCT GCAGGCATCG	7496
TGGTGTACAG CTCGTCGTTT GGTATGGCTT CATTCAGCTC CGGTTCCCAA	7546
CGATCAAGGC GAGTTACATG ATCCCCCATG TTGTGCAAAA AAGCGGTTAG	7596
CTCCTTCGGT CCTCCGATCG TTGTCAGAAG TAAGTTGGCC GCAGTGTTAT	7646
CACTCATGGT TATGGCAGCA CTGCATAATT CTCTTACTGT CATGCCATCC	7696

43

GTAAGATGCT TTTCTGTGAC TGGTGAGTAC TCAACCAAGT CATTCTGAGA	7746
ATAGTGTATG CGGCGACCGA GTTGCTCTTG CCCGGCGTCA ACACGGGATA	7796
ATACCGCGCC ACATAGCAGA ACTTTAAAAG TGCTCATCAT TGGAAAACGT	7846
TCTTCGGGGC GAAAACTCTC AAGGATCTTA CCGCTGTTGA GATCCAGTTC	7896
GATGTAACCC ACTCGTGCAC CCAACTGATC TTCAGCATCT TTTACTTTCA	7946
CCAGCGTTTC TGGGTGAGCA AAAACAGGAA GGCAAAATGC CGCAAAAAG	7996
GGAATAAGGG CGACACGGAA ATGTTGAATA CTCATACTCT TCCTTTTTCA	8046
ATATTATTGA AGCATTTATC AGGGTTATTG TCTCATGAGC GGATACATAT	8096
TTGAATGTAT TTAGAAAAAT AAACAAATAG GGGTTCCGCG CACATTTCCC	8146
CGAAAAGTGC CACCTGACGT CTAAGAAACC ATTATTATCA TGACATTAAC	8196
CTATAAAAAT AGGCGTATCA CGAGGCCCTT TCGTCTTCAA	8236

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 524 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Val	Pro	Gln	Ala	Leu	Leu	Phe	Val	Pro	Leu	Leu	Val	Phe	Pro
1				5					10					15
Leu	Cys	Phe	Gly	Lys	Phe	Pro	Ile	Tyr	Thr	Ile	Leu	Asp	Lys	Leu
				20					25					30
Gly	Pro	Trp	Ser	Pro	Ile	Asp	Ile	His	His	Leu	Ser	Cys	Pro	Asn
				35					40					45
Asn	Leu	Val	Val	Glu	Asp	Glu	Gly	Cys	Thr	Asn	Leu	Ser	Gly	Phe
				50					55					60
Ser	Tyr	Met	Glu	Leu	Lys	Val	Gly	Tyr	Ile	Leu	Ala	Ile	Lys	Met
				65					70					75

44

Asn	Gly	Phe	Thr	Cys	Thr	Gly	Val	Val	Thr	Glu	Ala	Glu	Thr	Tyr	80	85	90
Thr	Asn	Phe	Val	Gly	Tyr	Val	Thr	Thr	Thr	Phe	Lys	Arg	Lys	His	95	100	105
Phe	Arg	Pro	Thr	Pro	Asp	Ala	Cys	Arg	Ala	Ala	Tyr	Asn	Trp	Lys	110	115	120
Met	Ala	Gly	Asp	Pro	Arg	Tyr	Glu	Glu	Ser	Leu	His	Asn	Pro	Tyr	125	130	135
Pro	Asp	Tyr	Arg	Trp	Leu	Arg	Thr	Val	Lys	Thr	Thr	Lys	Glu	Ser	140	145	150
Leu	Val	Ile	Ile	Ser	Pro	Ser	Val	Ala	Asp	Leu	Asp	Pro	Tyr	Asp	155	160	165
Arg	Ser	Leu	His	Ser	Arg	Val	Phe	Pro	Ser	Gly	Lys	Cys	Ser	Gly	170	175	180
Val	Ala	Val	Ser	Ser	Thr	Tyr	Cys	Ser	Thr	Asn	His	Asp	Tyr	Thr	185	190	195
Ile	Trp	Met	Pro	Glu	Asn	Pro	Arg	Leu	Gly	Met	Ser	Cys	Asp	Ile	200	205	210
Phe	Thr	Asn	Ser	Arg	Gly	Lys	Arg	Ala	Ser	Lys	Gly	Ser	Glu	Thr	215	220	225
Cys	Gly	Phe	Val	Asp	Glu	Arg	Gly	Leu	Tyr	Lys	Ser	Leu	Lys	Gly	230	235	240
Ala	Cys	Lys	Leu	Lys	Leu	Cys	Gly	Val	Leu	Gly	Leu	Arg	Leu	Met	245	250	255
Asp	Gly	Thr	Trp	Val	Ala	Met	Gln	Thr	Ser	Asn	Glu	Thr	Lys	Trp	260	265	270
Cys	Pro	Pro	Asp	Gln	Leu	Val	Asn	Leu	His	Asp	Phe	Arg	Ser	Asp	275	280	285
Glu	Ile	Glu	His	Leu	Val	Val	Glu	Glu	Leu	Val	Arg	Lys	Arg	Glu	290	295	300
Glu	Cys	Leu	Asp	Ala	Leu	Glu	Ser	Ile	Met	Thr	Thr	Lys	Ser	Val	305	310	315
Ser	Phe	Arg	Arg	Leu	Ser	His	Leu	Arg	Lys	Leu	Val	Pro	Gly	Phe	320	325	330

45

Gly	Lys	Ala	Tyr	Thr	Ile	Phe	Asn	Lys	Thr	Leu	Met	Glu	Ala	Asp	335	340	345
Ala	His	Tyr	Lys	Ser	Val	Arg	Thr	Trp	Asn	Glu	Ile	Leu	Pro	Ser	350	355	360
Lys	Gly	Cys	Leu	Arg	Val	Gly	Gly	Arg	Cys	His	Pro	His	Val	Asn	365	370	375
Gly	Val	Phe	Phe	Asn	Gly	Ile	Ile	Leu	Gly	Pro	Asp	Gly	Asn	Val	380	385	390
Leu	Ile	Pro	Glu	Met	Gln	Ser	Ser	Leu	Leu	Gln	Gln	His	Met	Glu	395	400	405
Leu	Leu	Glu	Ser	Ser	Val	Ile	Pro	Leu	Val	His	Pro	Leu	Ala	Asp	410	415	420
Pro	Ser	Thr	Val	Phe	Lys	Asp	Gly	Asp	Glu	Ala	Glu	Asp	Phe	Val	425	430	435
Glu	Val	His	Leu	Pro	Asp	Val	His	Asn	Gln	Val	Ser	Gly	Val	Asp	440	445	450
Leu	Gly	Leu	Pro	Asn	Trp	Gly	Lys	Tyr	Val	Leu	Leu	Ser	Ala	Gly	455	460	465
Ala	Leu	Thr	Ala	Leu	Met	Leu	Ile	Ile	Phe	Leu	Met	Thr	Cys	Cys	470	475	480
Arg	Arg	Val	Asn	Arg	Ser	Glu	Pro	Thr	Gln	His	Asn	Leu	Arg	Gly	485	490	495
Thr	Gly	Arg	Glu	Val	Ser	Val	Thr	Pro	Gln	Ser	Gly	Lys	Ile	Ile	500	505	510
Ser	Ser	Trp	Glu	Ser	His	Lys	Ser	Gly	Gly	Glu	Thr	Arg	Leu		515	520	

## WHAT IS CLAIMED IS:

1. A recombinant adenovirus comprising an adenovirus containing a complete deletion of its E1 gene and at least a functional deletion of its E3 gene, and, in the site of the E1 gene deletion, a sequence comprising a non-adenovirus promoter directing the replication and expression of DNA encoding a heterologous protein from a disease-causing agent, which, when administered to the animal or human in said recombinant virus, elicits a substantially complete protective immune response against an agent causing said disease at a low dosage.
2. The recombinant adenovirus according to claim 1 wherein said promoter is selected from the group consisting of a cytomegalovirus promoter, an RSV promoter and an SV40 promoter.
3. The recombinant adenovirus according to claim 1, wherein the disease is rabies and the protein is a rabies virus glycoprotein.
4. The recombinant adenovirus according to claim 3, wherein the rabies virus protein is derived from the Evelyn Rockitniki Abelseth rabies strain.
5. The recombinant adenovirus according to claim 1 wherein said heterologous protein is selected from the group consisting of a protein from respiratory syncytial virus, human papilloma virus, or human immunodeficiency virus, and a tumor-associated protein specific for a selected malignancy.



6. The recombinant adenovirus according to claim 1, wherein the disease is human immunodeficiency virus (HIV) infection and the protein is HIV glycoprotein 120.

7. The recombinant adenovirus according to claim 1, wherein the disease is human papilloma virus infection and the protein is selected from the group consisting of E6, E7 and L1, and combinations thereof.

8. The recombinant adenovirus according to claim 1, wherein the disease is respiratory syncytial virus infection and the protein is selected from the group consisting of the glyco- (G) protein and the fusion (F) protein.

9. The recombinant adenovirus according to claim 1, wherein said adenovirus is Adrab.gp.

10. The use of the recombinant adenovirus of claims 1-9 in the manufacture of a pharmaceutical or veterinary product for the prevention or treatment of a disease.

11. A pharmaceutical or veterinary product comprising a recombinant adenovirus of claims 1-9.


12. The product according to claim 11, comprising a single dose of recombinant adenovirus between about  $10^4$  and about  $10^7$  pfu.

13. The product according to claim 11, wherein the adenovirus is formulated for either subcutaneous, rectal, intratracheal, intramuscular or intranasal administration.

14. A vaccine composition comprising a recombinant adenovirus comprising an adenovirus containing a complete deletion of its E1 gene and at least a functional deletion of its E3 gene, and, in the site of the E1 gene deletion, a sequence comprising a non-adenovirus promoter directing the replication and expression of DNA encoding a rabies virus G protein, which, when administered to a mammal in said recombinant virus, elicits a substantially complete protective immune response against rabies virus at a low dosage.


15. The composition according to claim 14 wherein said promoter is the CMV enhancer/promoter.

1 / 6



pSG5 rabp  
(1650 bp)

FIG. 1A




CUT OUT WITH Bgl II.

CUT pAdCMV.LacZ WITH  
Not I TO REMOVE LacZ  
GENE

FIG. 1B

rabgp GENE INSERTED BY  
BLUNT-END CLONING



HOMOLOGOUS RECOMBINATION WITH d17001

FIG. 1C




FIG. 1D

SUBSTITUTE SHEET (RULE 26)

2 / 6






FIG. 2



EFFECTOR: TARGET CELL RATIO

FIG. 3A



EFFECTOR: TARGET CELL RATIO

FIG. 3B

3 / 6




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F

4 / 6




FIG. 4G




FIG. 4H




FIG. 4I




FIG. 4J




FIG. 4K




FIG. 4L

5 / 6




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B

6 / 6




FIG. 7

SUBSTITUTE SHEET (RULE 26)



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/09495**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61K 39/12, 39/205, 39/235; C12N 7/01, 15/00, 15/09

US CL :424/199.1, 224.1, 233.1; 935/32, 34, 57, 65; 435/235.1, 320.1

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/199.1, 224.1, 233.1; 935/32, 34, 57, 65; 435/235.1, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS ONLINE, MEDLINE

search terms: Adenovirus, Vaccine, Rabies, E1, E3, Vector.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Prevec et al. A Recombinant Human Adenovirus Vaccine against Rabies. The Journal of Infectious Diseases. January 1990, Vol. 161, pages 27-30, especially page 28 and Figure 1.	1-4, 9, 14, 15
Y	Charlton et al. Oral rabies vaccination of skunks and foxes with a recombinant human adenovirus vaccine. Archives of Virology. 1992, Vol. 123, pages 169-179, especially see pages 170 start of the third paragraph, plus table 1 and 2.	1-4, 9, 14, 15

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

26 AUGUST 1996

Date of mailing of the international search report

04 OCT 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ALI SALIMI

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)\*

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/09495

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Eloit et al. Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine. Journal of General Virology. 1990, Vol. 71, pages 2425-2431, especially page 2429:Discussion.	5-8
Y	Johnson et al. Abundent Expression of Herpes Simplex Virus Glycoprotein gb Using an Adenovirus Vector. Virology. 1988, Vol. 164, pages 1-14, especially page 7.	5, 7, 8
Y	Dewar et al. Synthesis and processing of Human Immunodeficiency Virus Type 1 Envelope Proteins Encoded by a Recombinant Human Adenovirus. Journal of Virology. January 1989, Vol. 63, No. 1, pages 129-136, especially page 133.	6

Form PCT/ISA/210 (continuation of second sheet)(July 1992)★

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/09495

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☒ Claims Nos.: 10-13  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**THIS PAGE BLANK (USPTO)**